Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
Company profile
Ticker
LXEO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
LXEO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
424B3
Prospectus supplement
22 Apr 24
424B3
Prospectus supplement
22 Apr 24
8-K
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22 Apr 24
8-K
Departure of Directors or Certain Officers
22 Apr 24
424B3
Prospectus supplement
16 Apr 24
8-K
Other Events
16 Apr 24
EFFECT
Notice of effectiveness
15 Apr 24
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
Omega Fund VI, L.P.
14 Feb 24
SC 13G
Lundbeckfond Invest A/S
14 Feb 24
SC 13G
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G
D1 Capital Partners L.P.
14 Feb 24
SC 13G
Longitude Capital Partners IV, LLC
13 Feb 24
3
Tai Sandi See
6 Feb 24
4
REINALDO M DIAZ
6 Feb 24
4
Mette Kirstine Agger
6 Feb 24
4
Eric Adler
6 Feb 24
Financial summary
Quarter (USD) | Sep 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 38.70 mm | 38.70 mm | ||||
Cash burn (monthly) | 6.76 mm | 240.00 k | ||||
Cash used (since last report) | 46.74 mm | 1.66 mm | ||||
Cash remaining | -8.04 mm | 37.04 mm | ||||
Runway (months of cash) | -1.2 | 154.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Feb 24 | Eric Adler | Common Stock | Grant | Acquire A | No | No | 0 | 26,875 | 0.00 | 26,875 |
2 Feb 24 | Eric Adler | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 17 | 161,250 | 2.74 mm | 161,250 |
2 Feb 24 | Reinaldo M Diaz | Stock Option Common Stock | Grant | Acquire A | No | No | 17 | 36,000 | 612.00 k | 36,000 |
2 Feb 24 | Mette Kirstine Agger | Stock Option Common Stock | Grant | Acquire A | No | No | 17 | 36,000 | 612.00 k | 36,000 |
5 Jan 24 | Jenny Robertson | Common Stock | Grant | Acquire A | No | No | 0 | 23,750 | 0.00 | 23,750 |
5 Jan 24 | Jenny Robertson | Stock Option Common Stock | Grant | Acquire A | No | No | 14.48 | 142,500 | 2.06 mm | 142,500 |
News
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
22 Apr 24
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
12 Mar 24
RBC Capital Maintains Outperform on Lexeo Therapeutics, Raises Price Target to $24
12 Mar 24
Lexeo Therapeutics Q4 EPS $(0.86) Up From $(8.86) YoY
11 Mar 24
Lexeo Therapeutics Reveals Oversubscribed $95M Equity Financing
11 Mar 24
Press releases
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22 Apr 24
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy
16 Apr 24
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
13 Mar 24
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
11 Mar 24
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
11 Mar 24